Sarcoglycan
|
WikiDoc Resources for Sarcoglycan |
|
Articles |
|---|
|
Most recent articles on Sarcoglycan Most cited articles on Sarcoglycan |
|
Media |
|
Powerpoint slides on Sarcoglycan |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Sarcoglycan at Clinical Trials.gov Clinical Trials on Sarcoglycan at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Sarcoglycan
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Sarcoglycan Discussion groups on Sarcoglycan Patient Handouts on Sarcoglycan Directions to Hospitals Treating Sarcoglycan Risk calculators and risk factors for Sarcoglycan
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Sarcoglycan |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The sarcoglcyans are a family of five transmembrane proteins (α, β, γ, δ or ε) involved in the protein complex responsible for connecting the muscle fibre cytoskeleton to the extracellular matrix, preventing damage the muscle fibre sarcolemma through shearing forces.
Genetics
Mutations in the α, β, γ or δ genes (not ε) encoding these proteins can lead to the associated limb-girdle muscular dystrophy.